A

AbbVie

Global biopharmaceutical company developing medicines

Head of Commercial Sales Training & Development

Full-TimeUpdated on 10/23/2026
$182k - $346k/yr+ Long-term incentive program
Expert
Bachelor's, MBA
Irvine, CA, USA
Hybrid
TrainingInstructional Design & Curriculum Development

About the job

Requirements
  • A bachelor's degree is required; an MBA is preferred.
  • A minimum of 15 years of related experience in sales and/or sales leadership, training, and marketing in the aesthetics and/or pharmaceutical or medical device market.
  • A thorough knowledge of clinical and business development in the aesthetics industry, including knowledge of practitioners, retail, and sales and marketing practices.
  • Expertise in medical device and pharmaceutical sales and a clear understanding of Avamed and Pharma guidelines.
  • A clear understanding of navigating the aesthetics business and experience rolling out programs involving point of sales, patient consultation, patient recruitment, and patient rewards programs, with at least 4 to 6 years executing these programs.
  • A minimum of 15 years of combined field sales and sales management experience in aesthetics or medical device.
  • A minimum of 8 years of sales training, business training, and/or training leadership experience in aesthetics or pharmaceutical or medical device.
  • A minimum of 5 years leading leaders of teams to achieve training, sales, or marketing objectives.
  • Ability to develop a vision, mission, and purpose with a cross-functional team to achieve results across multiple objectives and workstreams.
  • Ability to partner cross-functionally and drive alignment in a matrix organization.
  • Leadership skills to direct the development of skills from entry level to senior level across the sales organization.
  • Oral and written communication skills for senior leadership audiences, including the ability to present to groups at various levels and sizes, internally and externally.
  • Managerial skills and the ability to work effectively with and through others, especially under project and meeting deadlines.
  • Planning and project management skills.
  • Analytical skills and working knowledge of sales and marketing plans and controls, as well as computer skills.
Responsibilities
  • Plan, develop, and direct the execution of training and development programs for the U.S. Aesthetics Sales Teams, including onboarding new sales representatives, developing existing representatives, and management and leadership development programs to build a pipeline of future people managers.
  • Set strategy and oversee clinical training across the Allergan Aesthetics portfolio, including training for internal teams and external customers on multiple devices and pharmaceutical products.
  • Develop and execute onboarding and ongoing business excellence education for Sales Representatives, RM, and Growth Services, including training on business development tools and the recruit, convert, retain methodology.
  • Develop and execute onboarding and development for front-line sales leaders.
  • Develop leadership programs for the first- and second-level leadership pipeline, including Director-level leaders, and for non-sales leaders across the commercial organization.
  • Lead the creative vision, strategy, and development of sales training programs aligned with business-unit strategic priorities.
  • Collaborate across the organization to develop and update training content and execution for Facial, SkinMedica, Body Contouring, PRM, and Inside Sales teams.
  • Spend field time with customers, managers, and representatives to evaluate training, meeting, and communication results and adjust programs accordingly.
  • Partner with Brand Marketing and Sales Leadership to set objectives, agendas, and workshops for sales meetings, including Manager Meetings, National Sales Meetings, product launches, and Inside Sales Team Meetings.
  • Develop pull-through plans with sales management and field training teams to reinforce meeting skills and ensure accountability.
  • Develop departmental standard operating procedures to measure and maintain standards for training, communications, and meetings.
  • Coordinate National FST and IST programs, including annual development meetings, onboarding, development, mentorship in training courses, and career development through key projects and preceptorships such as the Sales Training Preceptorship Program.
  • Lead development of the Sales Training Department development plan, talent planning, and strategic use of budget to meet sales-force development needs.
  • Serve as the main point of contact for outside vendors related to training and meeting engagement technology.
  • Maintain frequent contact with management and corporate personnel, including senior vice presidents, vice presidents, associate vice presidents, heads of sales, area sales directors, district sales managers, sales representatives, marketing directors, product managers, human resources, research and development, and sales and marketing managers from other divisions.
  • Engage with VIP customers, including health care professional course faculty.
Desired Qualifications
  • Marketing experience in aesthetics, medical device, or pharmaceuticals is preferred but not required.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.